Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 38Leukemia, Myeloid, Acute 38Multiple Myeloma 29Lymphoma 23Breast Neoplasms 19Colorectal Neoplasms 18Prostatic Neoplasms 17Pancreatic Neoplasms 17Myelodysplastic Syndromes 16Lymphoma, Large B-Cell, Diffuse 15Lung Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Burkitt Lymphoma 15Triple Negative Breast Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Melanoma 13Ovarian Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Sarcoma 10Neuroblastoma 9Neoplasms 9Lymphoma, T-Cell 9Glioma 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Leukemia, Biphenotypic, Acute 8Fallopian Tube Neoplasms 8Endometrial Neoplasms 8Myeloproliferative Disorders 7Lymphoma, Non-Hodgkin 7

Interventions

pevonedistat 1ibrutinib 1fludarabine phosphate 1Specimen Handling 1Pharmacogenomic Variants 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Biopsy × 90 days × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡